The company said, “The Company expects revenue to increase throughout fiscal 2026 as several major partnerships, clients, and pharmacy product lines that were planned and implemented in late 2025 and early 2026 go live. Based on current visibility and contracted activity, the Company expects revenue for the first quarter of fiscal 2026 to be in the range of approximately $25M to $28M…The Company recently completed a $15M bought deal financing led by Canaccord Genuity Corp. The proceeds provide additional working capital to support anticipated transaction volumes and ongoing operations. Management believes the Company is adequately capitalized to execute on its fiscal 2026 baseline outlook.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HYDTF:
- Hydreight Raises $15 Million in Oversubscribed Bought-Deal to Accelerate U.S. Digital Health Expansion
- Hydreight Raises C$10 Million in Bought Deal to Accelerate U.S. Digital Healthcare Growth
- Hydreight Moves Into At-Home STI Testing With Exclusive Deal and 50,000 Pre-Orders
- Hydreight enters distribution agreement with Health Screen Collective
- Hydreight Beats 2025 Targets With 1.3 Million Orders and Rapid License Growth